Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women

Nature Communications

Volumn 5, Issue , 2014, Pages

  Chen, Kexin ^a   Ma, Hongxia ^b   Li, Lian ^a   Zang, Rongyu ^c   Wang, Cheng ^b   Song, Fengju ^a   Shi, Tingyan ^c   Yu, Dianke ^d   Yang, Ming ^e   Xue, Wenqiong ^f   Dai, Juncheng ^b   Li, Shuang ^g   Zheng, Hong ^a   Wu, Chen ^d   Zhang, Ying ^f   Wu, Xiaohua ^c   Li, Dake ^h   Xue, Fengxia ^a   Li, Haixin ^a   Jiang, Zhi ^b   Liu, Jibin ⁱ   Liu, Yuexin ^j   Li, Pei ^a   Tan, Wen ^d   Han, Jing ^b   Jie, Jiang ^b   Hao, Quan ^a   Hu, Zhibin ^b   Lin, Dongxin ^d   Ma, Ding ^g   Jia, Weihua ^f   Shen, Hongbing ^b   Wei, Qingyi ^c,k   more..

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d CANCER HOSPITAL   (China)

^e BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^f SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

ⁱ NANTONG TUMOR HOSPITAL   (China)

^j UNIVERSITY OF TEXAS   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; GENETIC VARIATION; GENOME; HEALTH RISK; WOMENS HEALTH;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE REPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAN CHINESE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; ETHNOLOGY; GENE LOCUS; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED; NEOPLASM; OVARY TUMOR;

CHINA;

ANKRD3 PROTEIN, HUMAN; COL15A1 PROTEIN, HUMAN; COLLAGEN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; SRGAP1 PROTEIN, HUMAN; SURF6 PROTEIN, HUMAN;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; COLLAGEN; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GTPASE-ACTIVATING PROTEINS; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS;

EID: 84907365949     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5682     Document Type: Article

References (40)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
2. Sueblinvong, T. & Carney, M. E. Current understanding of risk factors for ovarian cancer. Curr. Treat. Options Oncol. 10, 67-81 (2009).
3. Lancaster, J. M. et al. Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol. Oncol. 107, 159-162 (2007). (Pubitemid 47575743)
4. Doherty, J. A. et al. ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. Cancer Epidemiol. Biomarkers Prev. 19, 245-250 (2010).
5. Ratner, E. et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 70, 6509-6515 (2010).
6. Braem, M. G., Schouten, L. J., Peeters, P. H., van den Brandt, P. A. & Onland-Moret, N. C. Genetic susceptibility to sporadic ovarian cancer: a systematic review. Biochim. Biophys. Acta 1816, 132-146 (2011).
7. Notaridou, M. et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int. J. Cancer 128, 2063-2074 (2011).
8. Cunningham, J. M. et al. Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br. J. Cancer 101, 1461-1468 (2009).
9. Lurie, G. et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. J. Int. Cancer 128, 936-943 (2011).
10. Phelan, C. M. et al. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol. Biomarkers Prev. 19, 600-604 (2010).
11. Schildkraut, J. M. et al. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS ONE 5, e10061 (2010).
12. Bolton, K. L. et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet. 42, 880-884 (2010).
13. Song, H. et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet. 41, 996-1000 (2009).
14. Goode, E. L. et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42, 874-879 (2010).
15. Pharoah, P. D. et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat. Genet. 45, 362-370 (2013).
16. Permuth-Wey, J. et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat. Commun. 4, 1627 (2013).
17. Bojesen, S. E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 45, 371-384 (2013).
18. Henderson, B. E., Lee, N. H., Seewaldt, V. & Shen, H. The influence of race and ethnicity on the biology of cancer. Nat. Rev. Cancer 12, 648-653 (2012).
19. Amenta, P. S. et al. Type XV collagen in human colonic adenocarcinomas has a different distribution than other basement membrane zone proteins. Hum. Pathol. 31, 359-366 (2000). (Pubitemid 30161356)
20. Amenta, P. S. et al. Loss of types XV and XIX collagen precedes basement membrane invasion in ductal carcinoma of the female breast. J. Pathol. 199, 298-308 (2003). (Pubitemid 36266852)
21. Harris, A., Harris, H. & Hollingsworth, M. A. Complete suppression of tumor formation by high levels of basement membrane collagen. Mol. Cancer Res. 5, 1241-1245 (2007).
22. Dunham, I. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
23. Consortium, E. P. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
24. Li, G. et al. ChIA-PET tool for comprehensive chromatin interaction analysis with paired-end tag sequencing. Genome Biol. 11, R22 (2010).
25. Gordon, K. J. & Blobe, G. C. Role of transforming growth factor-b superfamily signaling pathways in human disease. Biochim. Biophys. Acta 1782, 197-228 (2008).
26. Franzen, P. et al. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 75, 681-692 (1993).
27. Johnson, D. W., Qumsiyeh, M., Benkhalifa, M. & Marchuk, D. A. Assignment of human transforming growth factor-beta type I and type III receptor genes (TGFBR1 and TGFBR3) to 9q33-q34 and 1p32-p33, respectively. Genomics 28, 356-357 (1995).
28. Bristow, R. E., Baldwin, R. L., Yamada, S. D., Korc, M. & Karlan, B. Y. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer 85, 658-668 (1999). (Pubitemid 29075287)
29. Liao, R. Y. et al. TGFBR1*6A/9A polymorphism and cancer risk: a metaanalysis of 13,662 cases and 14,147 controls. Mol. Biol. Rep. 37, 3227-3232 (2010).
30. Wang, Y. Q., Qi, X. W., Wang, F., Jiang, J. & Guo, Q. N. Association between TGFBR1 polymorphisms and cancer risk: a meta-analysis of 35 case-control studies. PLoS ONE 7, e42899 (2012).
31. Seil, I. et al. The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. Int. J. Cancer 120, 2635-2642 (2007). (Pubitemid 46651285)
32. Theurillat, J. P. et al. Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. Int. J. Cancer 122, 1585-1591 (2008).
33. Moon, S. Y. & Zheng, Y. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol. 13, 13-22 (2003). (Pubitemid 35453891)
34. Fritz, G., Just, I. & Kaina, B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer 81, 682-687 (1999). (Pubitemid 29214373)
35. He, H. et al. SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J. Clin. Endocrinol. Metab. 98, E973-E980 (2013).
36. Wong, K. et al. Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway. Cell 107, 209-221 (2001). (Pubitemid 33035947)
37. Canet, B., Pons, C., Espinosa, I. & Prat, J. CDC42-positive macrophages may prevent malignant transformation of ovarian endometriosis. Hum. Pathol. 43, 720-725 (2012).
38. Yuzhalin, A. E. & Kutikhin, A. G. ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia. Asian Pac. J. Cancer Prev. 13, 5091-5096 (2012).
39. Gates, M. A., Wolpin, B. M., Cramer, D. W., Hankinson, S. E. & Tworoger, S. S. ABO blood group and incidence of epithelial ovarian cancer. Int. J. Cancer 128, 482-486 (2011).
40. Poole, E. M. et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control 23, 1805-1810 (2012).